Pharma BD Deal Intelligence

Novartis AG / Arrowhead Pharmaceuticals Inc.

2025 · Licensing/Option · $2.2B · Complete

Arrowhead Pharmaceuticals and Novartis entered a global license and collaboration agreement granting Novartis an exclusive worldwide license to research, develop, manufacture and commercialize ARO-SNCA, a preclinical-stage RNAi candidate built on Arrowhead's TRiM platform for subcutaneous administration and CNS delivery, targeting the gene encoding alpha-synuclein for Parkinson's disease and other synucleinopathies. Novartis paid $200 million upfront on closing, with Arrowhead eligible for up to $2 billion in development, regulatory and sales milestones plus tiered royalties on commercial sales up to the low double digits. The agreement closed October 21, 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Novartis AG deals